Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study-Reference-Cited by-同舟云学术

Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study

Published:2004-03 Issue:3 Volume:48 Page:780-782
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pletz Mathias W. R.¹,De Roux Andres¹,Roth Andreas²,Neumann Karl-Heinz¹,Mauch Harald²,Lode Hartmut¹

Affiliation:

1. Department of Chest and Infectious Diseases, City Hospital Emil von Behring/Chest Hospital Heckeshorn

2. Institute of Microbiology, City Hospital Emil von Behring, Freie Universität Berlin, 14195 Berlin, Germany

Abstract

ABSTRACT Moxifloxacin is the most active fluoroquinolone against Mycobacterium tuberculosis in vitro. However, data about the efficacy in patients are not available. We enrolled 17 patients with tuberculosis in a prospective, randomized study. After 5 days of monotherapy with either moxifloxacin or isoniazid, we detected significant decreases in mean CFU per milliliter in sputum in both groups. The calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log 10 CFU per ml of sputum per day, respectively. According to the data from our study, moxifloxacin exhibits an early bactericidal activity that is comparable to that of isoniazid.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.48.3.780-782.2004

Reference14 articles.

1. Crofton J. P. Chaulet and D. Maher. 1997. Guidelines for the managment of drug-resistant tuberculosis. World Health Organization Geneva Switzerland.

2. Gillespie, S. H., and O. Billington. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother.44:393-395.

3. Gillespie, S. H., R. D. Gosling, and B. M. Charalambous. 2002. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. Am. J. Respir. Crit. Care Med.166:31-35.

4. Hafner, R., J. A. Cohn, D. J. Wright, N. E. Dunlap, M. J. Egorin, M. E. Enama, K. Muth, C. A. Peloquin, N. Mor, L. B. Heifets, et al. 1997. Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. Am. J. Respir. Crit. Care Med.156:918-923.

5. Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update to Novel Therapeutic Options for Combating Tuberculosis: Challenges and Future Prospectives;Current Pharmaceutical Biotechnology;2024-10

2. Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial;Trials;2024-05-08

3. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs;European Respiratory Journal;2023-06-15

4. Updated considerations in the diagnosis and management of tuberculosis infection and disease: integrating the latest evidence-based strategies;Expert Review of Anti-infective Therapy;2023-05-08

5. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs;2023-01-20